Infinata, A Part of The Financial Times GroupBioPharm Insight        

 

 

 

 

 

 

 

 

BioPharm Insight
The Leading Provider of Intelligence to the Biotechnology & Pharmaceutical Industry

Pharmawire Intelligence

Endocyte narrows CRO search for Phase III ovarian cancer trial; financing still being secured, CFO says

Kissei working with CRO Richmond Pharmacology for Phase I endometriosis trial; recruitment delays occurring

Oculus looks for opportunistic buys but synergistic alliances are current focus - CEO

 
Home | About Us | Contact
Other Offerings: BioPharm Clinical | BioPharm Devices

(C) 2010 Infinata. All rights reserved.